Tiziana life sciences announces foralumab presentation by dr. howard weiner at the annual meeting of the international society of neuroimmunology

New york, aug. 23, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced an oral presentation of “nasal anti-cd3 mab induces tregs that dampen microglial activation and treat neuroinflammatory diseases including ms, ad and als” at the 16th international society of neuroimmunology (isni) congress in quebec city, canada, being held august 21-24, 2023. dr. weiner's live presentation is scheduled for 11:42 a.m. et on august 24, 2023.
TLSA Ratings Summary
TLSA Quant Ranking